Ar­ray shows off the pos­i­tive BEA­CON CRC da­ta that helped spur Pfiz­er's $11.4B buy­out of­fer

In­ves­ti­ga­tors took cen­ter stage at a sci­en­tif­ic con­fer­ence to­day to tout the pos­i­tive da­ta from the BEA­CON CRC tri­al of Ar­ray’s BRAF/MEK triplet for drug re­sis­tant colon can­cer that played a key role in at­tract­ing Pfiz­er’s $11.4 bil­lion buy­out bid.

The FDA had al­ready stamped its break­through des­ig­na­tion on the triple ther­a­py of (Braftovi) en­co­rafenib in com­bi­na­tion with (Mek­tovi) binime­tinib and ce­tux­imab be­fore Pfiz­er ex­ecs were pro­vid­ed a glimpse of the top-line re­sults in May — whet­ting their ap­petite for the ac­qui­si­tion dur­ing the fi­nal days of their ne­go­ti­a­tions. That’s when they learned that the triplet scored a me­di­an over­all sur­vival rate of 9 months among drug re­sis­tant pa­tients with BRAF V600E-mu­tat­ed cas­es of col­orec­tal can­cer com­pared to 5.4 months for the stan­dard of care. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.